Amlodipine And Atorvastatin Tablet, Film Coated
Product Images NDC 72162-2093

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Amlodipine And Atorvastatin (NDC 72162-2093). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Amlodipine Besylate And Atorvastatin Calcium 02)

A Kaplan-Meier survival curve comparing event rates over 24 months between Amlodipine and placebo groups. The plot shows event rate on the vertical axis and time in months on the horizontal axis, with numbers at risk noted below the time axis. The graph includes statistical data: P-value=0.003, Hazard Ratio=0.691, and 95% Confidence Interval of 0.54 to 0.88.*

FDA Label Image

Figure 2 (Amlodipine Besylate And Atorvastatin Calcium 03)

A forest plot chart illustrating hazard ratios with 95% confidence intervals comparing Amlodipine versus placebo across various patient subgroups, including overall, age groups, gender, baseline sitting systolic blood pressure, baseline vessel disease, baseline vessels with stenosis, and PCI-stent strata. The x-axis represents the hazard ratio scale from 0 to 2.*

FDA Label Image

Figure 3 (Amlodipine Besylate And Atorvastatin Calcium 04)

A line graph comparing cumulative incidence over time (in years) between two groups: Atorvastatin and Placebo. The graph shows percentage cumulative incidence on the vertical axis and time in years on the horizontal axis. Atorvastatin has a lower cumulative incidence than Placebo over 3.5 years, with a hazard ratio (HR) of 0.64 (0.50-0.83) and p=0.0005.*

FDA Label Image

Figure 4 (Amlodipine Besylate And Atorvastatin Calcium 05)

A line graph depicting cumulative hazard percentage over time in years, comparing Atorvastatin and Placebo groups. The X-axis shows time to first primary endpoint through four years of follow-up, while the Y-axis represents cumulative hazard. The graph includes a hazard ratio (HR) of 0.63 with a confidence interval (0.48-0.83) and a p-value of 0.001.*

FDA Label Image

Figure 5 (Amlodipine Besylate And Atorvastatin Calcium 06)

A line graph comparing the percentage of subjects experiencing the first major cardiovascular event over time (0 to 5 years) for Atorvastatin 10 mg and Atorvastatin 80 mg. The graph shows two lines: a dashed line for 10 mg and a solid line for 80 mg dose, with a hazard ratio (HR) of 0.78 and a P-value of 0.0002 indicated in the lower right corner.*

FDA Label Image

Amlodipine (Amlodipine)

Chemical structure diagram showing two molecular formulas: one complex organic molecule with a chlorine atom and multiple functional groups, and a separate sulfonic acid group attached to a benzene ring. This likely represents the combined chemical structures of the active ingredients in Amlodipine and Atorvastatin tablets.*

FDA Label Image

Atorvastatin-glycol-solvate (Atorvastatin Glycol Solvate)

Chemical structure of Amlodipine and Atorvastatin, depicting two molecules of the calcium salt form and one molecule of a co-crystallizing agent, likely representing the atorvastatin calcium complex used in the combination tablet.*

FDA Label Image

Label (Lbl721622093)

Label for Amlodipine and Atorvastatin Tablets USP, 5 mg/20 mg film-coated tablets, oral use. The label shows the NDC 72162-2093-3 and states the package contains 30 tablets. It is relabeled by Bryant Ranch Prepack, Inc. and manufactured by Apotex Inc. Storage instructions and warnings to keep medication out of reach of children are included.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.